Most cancer therapies work for the people who can reach them. We started from the other end: what could the whole world afford?
Why rice
Half the world eats rice, and milling it leaves an enormous, renewable by-product stream — produced everywhere, all the time, near the people who would need what it might yield.
A compound sourced from that stream starts abundant, cheap, and local. That is the thesis: affordability as a starting constraint, not a distribution problem for later.
Where the evidence stands
Laboratory work, running now. No human trials. No candidate therapy. Nothing shown to treat any disease in any person.
We are not naming cancer types or compounds yet — that would claim a confidence the evidence has not earned. Results will be named when they are real, along with whatever failed.
Why say anything now
Because announcing only successes is how research looks more certain than it is.
This note is the record of the attempt, and it will be updated as the evidence moves — in either direction.
Where Lunas comes in
The rule that governs Stethos governs this programme: claims carry evidence, and refusal is an answer.
If the science ever holds, affordability is what turns a finding into access — and access is the reason Lunas exists.
What this deliberately does not do
- No efficacy demonstrated — nothing here treats or prevents anything
- No human trials; no treatment exists or is available
- Never a substitute for oncology care — decisions belong with your oncologist
- Eating rice or rice bran is not a cancer therapy